Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 110,000 ordinary shares of 25 pence each.
- Purchase Date: October 31, 2008.
- Purchase Price: 1,176.54 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,215,787,438 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 110,000 repurchased shares. Consequently, the total number of shares in issue remains 5,215,787,438, while the Treasury holding stands at 474,194,158 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,215,787,438) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the Treasury share count (474,194,158) and its percentage of total voting rights (9.09%).
- Note that this filing is a transactional report and does not contain operational or financial performance data for the period.